Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to stifle him.US Economyread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
These are the stocks posting the largest moves midday.Market Insiderread more
The Supreme Court refused to overturn a precedent that strengthened the power of government regulators in a closely watched case that could have had broad ramifications for...Politicsread more
Shares of Paychex dropped on Wednesday after Bank of America downgraded the stock due to its "excessive valuation" and "underwhelming fundamentals."Marketsread more
A full-time worker earning the federal minimum wage of $7.25 per hour cannot rent an affordable two-bedroom apartment anywhere in the country, where affordable is defined as...Spendread more
The president raised $6 million alone at a fundraiser he attended at the Trump International Hotel on Tuesday in Washington.Politicsread more
Carl Icahn has hired Harvard geneticist Richard Mulligan as a portfolio manager, signaling an increased focus from the billionaire activist investor on an industry he's largely ignored for several years.
Mulligan is no stranger to Icahn. He worked with the billionaire on multiple biotech targets, from ImClone Systems — sold to Eli Lilly in 2008 for $6.5 billion — to Biogen, where Mulligan is still a director.
Mulligan worked closely with former Icahn deputy Alex Denner, who left to form Sarissa Capital in 2012. Mulligan was senior managing director at Sarissa Capital from 2013 to 2016, according to a statement Wednesday from Icahn, who said, "We are very pleased to have Richard join Icahn Capital given the depth and level of experience he brings as we look to enhance our focus on the biotechnology sector."
Icahn recently took a large stake in Bristol-Myers Squibb, according to The Wall Street Journal, which reported the activist believes the company may be ripe for a takeover. Icahn's thesis in biotech investing generally has been that smaller companies should be sold to larger ones, a strategy he put to work in sales of ImClone to Lilly, MedImmune to AstraZeneca, Genzyme to Sanofi and Amylin to Bristol-Myers.
Since Denner and Mulligan left, Icahn hasn't focused as much on the biotech world. Hiring Mulligan — a professor emeritus at Harvard Medical School and visiting scientist at the Koch Institute for Integrative Cancer Research at MIT, signals he may be back, at a time when biotech valuations are 25 percent off their 2015 highs.